Pieris Pharmaceuticals is a biotechnology company that discovers and develops Anticalin-based drugs to target validated disease pathways. Co.'s clinical pipeline includes elarekibep an inhaled IL-4Ra antagonist Anticalin protein to treat uncontrolled asthma, PRS-220, an inhaled CTGF antagonist to treat IPF and other forms for fibrotic lung disease, an immuno-oncology (IO) bispecific PRS-344/S095012 targeting PD-L1 and 4-1BB. Co. has intellectual property rights directed to various aspects of its Anticalin technology platform, allowing for the development and improvement of both its platform and drug candidates. Co.'s development plans focus on its clinical and preclinical programs. We show 42 historical shares outstanding datapoints in our PIRS shares outstanding history coverage, used to compute PIRS market cap on those dates.
Understanding the changing numbers of shares outstanding, the changing
share price, and the resulting changing PIRS market cap history over the course of time is important for investors
interested in comparing PIRS's market cap history versus its peers.
Many "beginner" or "novice" investors will look at one stock trading at a price of $10 per share and another trading at
a price of $20 per share and think the latter company is worth twice as much. Of course, that is a completely meaningless comparison without also knowing how many shares outstanding there are for each of the two companies,
and then calculating their respective market caps. Comparing the share price of PIRS versus a peer is one thing; comparing
PIRS market cap versus a peer is a completely different story.
Furthermore, via fluctuation both in per-share price and in the number of shares outstanding (via issuance of new shares over time, the repurchase of existing shares),
the market cap for a company like PIRS can fluctuate over the course of history.
With this page we aim to empower investors researching PIRS by allowing them to research the PIRS market cap history. |
Free PIRS Email Alerts:
Video: The Importance of Market Cap
